161 related articles for article (PubMed ID: 38388484)
1. LAPTM4B-mediated hepatocellular carcinoma stem cell proliferation and MDSC migration: implications for HCC progression and sensitivity to PD-L1 monoclonal antibody therapy.
Wang H; Zhou Q; Xie DF; Xu Q; Yang T; Wang W
Cell Death Dis; 2024 Feb; 15(2):165. PubMed ID: 38388484
[TBL] [Abstract][Full Text] [Related]
2. Fibrotic immune microenvironment remodeling mediates superior anti-tumor efficacy of a nano-PD-L1 trap in hepatocellular carcinoma.
Liu X; Zhou J; Wu H; Chen S; Zhang L; Tang W; Duan L; Wang Y; McCabe E; Hu M; Yu Z; Liu H; Choi CHJ; Sung JJ; Huang L; Liu R; Cheng AS
Mol Ther; 2023 Jan; 31(1):119-133. PubMed ID: 36146933
[TBL] [Abstract][Full Text] [Related]
3. IL-1β-Induced Elevation of Solute Carrier Family 7 Member 11 Promotes Hepatocellular Carcinoma Metastasis Through Up-regulating Programmed Death Ligand 1 and Colony-Stimulating Factor 1.
He Q; Liu M; Huang W; Chen X; Zhang B; Zhang T; Wang Y; Liu D; Xie M; Ji X; Sun M; Tian D; Xia L
Hepatology; 2021 Dec; 74(6):3174-3193. PubMed ID: 34288020
[TBL] [Abstract][Full Text] [Related]
4. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.
Liu M; Zhou J; Liu X; Feng Y; Yang W; Wu F; Cheung OK; Sun H; Zeng X; Tang W; Mok MTS; Wong J; Yeung PC; Lai PBS; Chen Z; Jin H; Chen J; Chan SL; Chan AWH; To KF; Sung JJY; Chen M; Cheng AS
Gut; 2020 Feb; 69(2):365-379. PubMed ID: 31076403
[TBL] [Abstract][Full Text] [Related]
5. Interventing mitochondrial PD-L1 suppressed IFN-γ-induced cancer stemness in hepatocellular carcinoma by sensitizing sorafenib-induced ferroptosis.
Li T; Huang HY; Qian B; Wang WH; Yuan Q; Zhang HY; He J; Ni KJ; Wang P; Zhao ZY; He JL; Fu SW; Xu L; Lin YC; Lin ZN
Free Radic Biol Med; 2024 Feb; 212():360-374. PubMed ID: 38171407
[TBL] [Abstract][Full Text] [Related]
6. Oxaliplatin-Resistant Hepatocellular Carcinoma Drives Immune Evasion Through PD-L1 Up-Regulation and PMN-Singular Recruitment.
Zhang F; Hu K; Liu W; Quan B; Li M; Lu S; Chen R; Ren Z; Yin X
Cell Mol Gastroenterol Hepatol; 2023; 15(3):573-591. PubMed ID: 36513250
[TBL] [Abstract][Full Text] [Related]
7. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
8. MTDH antisense oligonucleotides reshape the immunosuppressive tumor microenvironment to sensitize Hepatocellular Carcinoma to immune checkpoint blockade therapy.
Wan JL; Wang B; Wu ML; Li J; Gong RM; Song LN; Zhang HS; Zhu GQ; Chen SP; Cai JL; Xing XX; Wang YD; Yang Y; Cai CZ; Huang R; Liu H; Dai Z
Cancer Lett; 2022 Aug; 541():215750. PubMed ID: 35609735
[TBL] [Abstract][Full Text] [Related]
9. HSF1 is involved in immunotherapeutic response through regulating APOJ/STAT3-mediated PD-L1 expression in hepatocellular carcinoma.
Cheng H; Wang S; Huang A; Ma J; Gao D; Li M; Chen H; Guo K
Cancer Biol Ther; 2023 Dec; 24(1):1-9. PubMed ID: 36482717
[TBL] [Abstract][Full Text] [Related]
10. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.
Liu H; Shen J; Lu K
Biochem Biophys Res Commun; 2017 Apr; 486(2):239-244. PubMed ID: 28254435
[TBL] [Abstract][Full Text] [Related]
11. LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma.
Yang H; Xiong FX; Lin M; Yang Y; Nie X; Zhou RL
J Cancer Res Clin Oncol; 2010 Feb; 136(2):275-81. PubMed ID: 19690886
[TBL] [Abstract][Full Text] [Related]
12. AP4 positively regulates LAPTM4B to promote hepatocellular carcinoma growth and metastasis, while reducing chemotherapy sensitivity.
Meng Y; Wang L; Xu J; Zhang Q
Mol Oncol; 2018 Mar; 12(3):373-390. PubMed ID: 29337428
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma.
Tan S; Guo X; Bei C; Zhang H; Li D; Zhu X; Tan H
BMC Cancer; 2022 Aug; 22(1):905. PubMed ID: 35986302
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of METTL5 inhibits the Myc pathway to downregulate PD-L1 expression and inhibits immune escape of hepatocellular carcinoma cells.
Xu W; Liu S; Zhang G; Liu J; Cao G
J Chemother; 2023 Sep; 35(5):455-464. PubMed ID: 36369791
[TBL] [Abstract][Full Text] [Related]
15. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.
Zhang W; Liu Y; Yan Z; Yang H; Sun W; Yao Y; Chen Y; Jiang R
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581055
[TBL] [Abstract][Full Text] [Related]
16. The current status and future of PD-L1 in liver cancer.
Hao L; Li S; Deng J; Li N; Yu F; Jiang Z; Zhang J; Shi X; Hu X
Front Immunol; 2023; 14():1323581. PubMed ID: 38155974
[TBL] [Abstract][Full Text] [Related]
17. Construction and validation of a novel lysosomal signature for hepatocellular carcinoma prognosis, diagnosis, and therapeutic decision-making.
Chen J; Gao G; He Y; Zhang Y; Wu H; Dai P; Zheng Q; Huang H; Weng J; Zheng Y; Huang Y
Sci Rep; 2023 Dec; 13(1):22624. PubMed ID: 38114725
[TBL] [Abstract][Full Text] [Related]
18. FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2.
Xie M; Lin Z; Ji X; Luo X; Zhang Z; Sun M; Chen X; Zhang B; Liang H; Liu D; Feng Y; Wang Y; Li Y; Liu B; Huang W; Xia L
J Hepatol; 2023 Jul; 79(1):109-125. PubMed ID: 36907560
[TBL] [Abstract][Full Text] [Related]
19. N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment.
Shi Y; Wang Y; Zhang W; Niu K; Mao X; Feng K; Zhang Y
Front Endocrinol (Lausanne); 2023; 14():1153802. PubMed ID: 37469973
[TBL] [Abstract][Full Text] [Related]
20. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
